# Yan Song

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/yan-song/

## Facts

| Field | Value |
| --- | --- |
| Citations | 2,451 |
| Field | Renal cell carcinoma treatment |
| h-index | 26 |
| i10-index | 62 |
| Last Known Institution | Hubei University of Science and Technology |
| OpenAlex ID | https://openalex.org/A5037870558 |
| ORCID iD | 0000-0002-7566-2813 |
| Works | 206 |

## Researcher papers

- [Loss of FOXA1/2 Is Essential for the Epithelial-to-Mesenchymal Transition in Pancreatic Cancer](https://scholariq.org/papers/loss-of-foxa1-2-is-essential-for-the-epithelial-to-mesenchymal-transition-in/)
- [Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double‐blind randomized phase 2 trial](https://scholariq.org/papers/anlotinib-for-previously-treated-advanced-or-metastatic-esophageal-squamous-cell/)
- [Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial](https://scholariq.org/papers/anlotinib-versus-sunitinib-as-first-line-treatment-for-metastatic-renal-cell/)
- [PDX1 dynamically regulates pancreatic ductal adenocarcinoma initiation and maintenance](https://scholariq.org/papers/pdx1-dynamically-regulates-pancreatic-ductal-adenocarcinoma-initiation-and/)
- [What are the clinical symptoms and physical signs for non‐small cell lung cancer before diagnosis is made? A nation‐wide multicenter 10‐year retrospective study in China](https://scholariq.org/papers/what-are-the-clinical-symptoms-and-physical-signs-for-non-small-cell-lung-cancer/)
- [Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States](https://scholariq.org/papers/cost-effectiveness-analysis-of-semaglutide-2-4-mg-for-the-treatment-of-adult/)
- [Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT).](https://scholariq.org/papers/results-of-the-phase-iii-placebo-controlled-trial-succeed-evaluating-the-mtor/)
- [Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements](https://scholariq.org/papers/systemic-therapy-for-hepatocellular-carcinoma-chinese-consensus-based/)
- [Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis](https://scholariq.org/papers/comparative-efficacy-of-jak-inhibitors-for-moderate-to-severe-rheumatoid/)
- [Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs](https://scholariq.org/papers/effects-of-upadacitinib-on-patient-reported-outcomes-results-from-select-beyond/)
- [Real-world perioperative treatment patterns and economic burden of recurrence in early-stage HER2-negative breast cancer: a SEER-Medicare study](https://scholariq.org/papers/real-world-perioperative-treatment-patterns-and-economic-burden-of-recurrence-in/)

## Researcher topics

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Pneumonia and Respiratory Infections](https://scholariq.org/topics/pneumonia-and-respiratory-infections/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Economic and Financial Impacts of Cancer](https://scholariq.org/topics/economic-and-financial-impacts-of-cancer/)

## Researcher university

- [Hubei University of Science and Technology](https://scholariq.org/institutions/hubei-university-of-science-and-technology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.